DK3331528T3 - Muskarinagonister - Google Patents

Muskarinagonister Download PDF

Info

Publication number
DK3331528T3
DK3331528T3 DK16750221.0T DK16750221T DK3331528T3 DK 3331528 T3 DK3331528 T3 DK 3331528T3 DK 16750221 T DK16750221 T DK 16750221T DK 3331528 T3 DK3331528 T3 DK 3331528T3
Authority
DK
Denmark
Prior art keywords
muscarinagonists
Prior art date
Application number
DK16750221.0T
Other languages
Danish (da)
English (en)
Inventor
Giles Albert Brown
Miles Stuart Congreve
Mark Pickworth
Mark Rackham
Benjamin Gerald Tehan
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Application granted granted Critical
Publication of DK3331528T3 publication Critical patent/DK3331528T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK16750221.0T 2015-08-03 2016-08-03 Muskarinagonister DK3331528T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1513740.9A GB201513740D0 (en) 2015-08-03 2015-08-03 Muscarinic agonist
PCT/GB2016/052384 WO2017021728A1 (en) 2015-08-03 2016-08-03 Muscarinic agonists

Publications (1)

Publication Number Publication Date
DK3331528T3 true DK3331528T3 (da) 2021-10-25

Family

ID=54063147

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16750221.0T DK3331528T3 (da) 2015-08-03 2016-08-03 Muskarinagonister

Country Status (10)

Country Link
US (2) US10548884B2 (enExample)
EP (1) EP3331528B1 (enExample)
JP (1) JP6847093B2 (enExample)
CN (1) CN107949384B (enExample)
AU (1) AU2016302047B2 (enExample)
CA (1) CA2994143C (enExample)
DK (1) DK3331528T3 (enExample)
ES (1) ES2894855T3 (enExample)
GB (1) GB201513740D0 (enExample)
WO (1) WO2017021728A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104039321B (zh) 2011-11-18 2017-02-22 赫普泰雅治疗有限公司 药物化合物
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
AU2018300980A1 (en) 2017-07-12 2020-01-02 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
ES3064093T3 (en) 2017-10-20 2026-04-22 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
WO2019126559A1 (en) 2017-12-20 2019-06-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
ES2942837T3 (es) 2018-03-23 2023-06-07 Pfizer Derivados de azaespiro piperazina
GB201810239D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CA3155177A1 (en) * 2019-09-25 2021-04-01 Oncoarendi Therapeutics S.A. Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-1,2,4-triazol-3-amine
CN114555592B (zh) * 2019-10-09 2024-09-06 诺华股份有限公司 作为m4激动剂的2-氮杂螺[3.4]辛烷衍生物
PE20221454A1 (es) * 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
TW202134231A (zh) 2019-12-06 2021-09-16 美商紐羅克里生物科學有限公司 蕈毒受體4拮抗劑及使用方法
JP7707176B2 (ja) * 2020-02-05 2025-07-14 ニューロクライン バイオサイエンシーズ,インコーポレイテッド ムスカリン性受容体4アンタゴニストおよび使用方法
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
CN121605195A (zh) * 2023-08-03 2026-03-03 纽罗克里生物科学有限公司 合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1987034B1 (en) * 2006-02-22 2011-07-20 Vertex Pharmceuticals Incorporated Spiro condensed piperidines as modulators of muscarinic receptors
AU2007221214A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2009309988A1 (en) 2008-10-29 2010-05-06 Grunenthal Gmbh Substituted spiroamines
FR2945531A1 (fr) 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
CN104039321B (zh) * 2011-11-18 2017-02-22 赫普泰雅治疗有限公司 药物化合物
DK2897948T3 (en) * 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
CN105189482A (zh) * 2013-02-07 2015-12-23 武田药品工业株式会社 作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯
EP3102568B1 (en) * 2014-02-06 2018-06-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist

Also Published As

Publication number Publication date
JP6847093B2 (ja) 2021-03-24
JP2018522034A (ja) 2018-08-09
ES2894855T3 (es) 2022-02-16
AU2016302047A8 (en) 2018-03-08
AU2016302047B2 (en) 2020-09-10
CA2994143C (en) 2023-09-26
US10548884B2 (en) 2020-02-04
EP3331528B1 (en) 2021-09-29
AU2016302047A1 (en) 2018-02-15
CN107949384B (zh) 2025-02-28
HK1250139A1 (en) 2018-11-30
WO2017021728A9 (en) 2017-04-27
EP3331528A1 (en) 2018-06-13
US20200129496A1 (en) 2020-04-30
CN107949384A (zh) 2018-04-20
CA2994143A1 (en) 2017-02-09
GB201513740D0 (en) 2015-09-16
US11324738B2 (en) 2022-05-10
US20180228791A1 (en) 2018-08-16
WO2017021728A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
FIC20240028I1 (fi) Retifanlimabi
NL301262I2 (nl) Pirtobrutinib
DK3283625T3 (da) Nukleasemedieret genomeditering
EP3286361A4 (en) Cancer neoepitopes
DK3331869T3 (da) Muscarinagonister
FIC20265011I1 (fi) Nipokalimabi
DK3277719T3 (da) Polypeptider
EP3316375A4 (en) Redox flow cell
DK3360890T3 (da) Genterapi
DK3305788T3 (da) Janus-kinase-hæmmer
DK3331529T3 (da) Muskarinagonister
EP3290364A4 (en) Conveyor belt wear monitoring system
DK3310450T3 (da) Olie-vand-separator
DK3394281T3 (da) Gærcelle
DK3270930T3 (da) Præeklampsi
EP3381654A4 (en) Liquid blow molding method
EP3393959A4 (en) GRAB
EP3363322A4 (en) Hair extender
DK3292136T3 (da) Penicillin-g-acylaser
DK3274482T3 (da) Stenborsknop
DE112015006486A5 (de) Inkubationsrinne
EP3390373C0 (en) DOTA SUMMARY
EP3548009A4 (en) POLYMERIC NANOPARTICLES
EP3297518B1 (en) VIDEO LARYNGOSCOPES
EP3377179A4 (en) DEUTERED EPI-743